SCHEMBL17563261

SCHEMBL17563261

Cc1ccnc(F)c1Br

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15929893 0.77 NOS2 (0.48)
SCHEMBL31555027 0.75
SCHEMBL31527977 0.75
SCHEMBL29843421 0.75
SCHEMBL6938070 0.75
SCHEMBL31555002 0.75
SCHEMBL3015741 0.75
SCHEMBL15817465 0.75
SCHEMBL20836126 0.75
SCHEMBL8062044 0.75

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112159421-A Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid 珠海奥博凯生物医药技术有限公司 2021-01-01 CN claimed
EP-4688754-A1 KCC2 POTENTIATORS AND USES THEREOF Axonis Therapeutics, Inc. (US) 2026-02-11 EP disclosed
EP-4329877-B1 SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY ALKERMES INC (US) 2026-02-04 EP disclosed
US-20260028351-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. 2026-01-29 US disclosed
EP-4665453-A1 GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2025-12-24 EP disclosed
US-20250304574-A1 3,4,6,7-TETRAHYDRO-2,7-NAPHTHYRIDINE-2(1H)-CARBOXAMIDE DERIVATIVES AS GPR65 INHIBITORS FOR THE TREATMENT OF CANCER AND AUTOIMMUNE DISEASES Pathios Therapeutics Limited (GB) 2025-10-02 US disclosed
EP-4587014-A2 C5AR1 ANTAGONISTS AND USES THEREOF Vanqua Bio, Inc. (US) 2025-07-23 EP disclosed
US-20240368182-A1 Substituted Macrocyclic Compounds and Related Methods of Treatment JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2024-11-07 US disclosed
WO-2024211744-A1 KCC2 POTENTIATORS AND USES THEREOF AXONIS THERAPEUTICS, INC. (US) 2024-10-10 WO disclosed
US-20240317752-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2024-09-26 US disclosed
EP-3737684-B1 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES IDORSIA PHARMACEUTICALS LTD (CH) 2022-11-16 EP disclosed
WO-2022232025-A1 SUBSTITUTED AMIDE MACROCYCLIC COMPOUNDS WITH OREXIN-2 RECEPTOR AGONIST ACTIVITY ALKERMES, INC. (US) 2022-11-03 WO disclosed
WO-2022178256-A1 6-SUBSTITUTED-9H-PURINE DERIVATIVES AND RELATED USES BLACK DIAMOND THERAPEUTICS, INC. (US) 2022-08-25 WO disclosed
WO-2022140316-A1 SUBSTITUTED MACROCYCLIC COMPOUNDS AND RELATED METHODS OF TREATMENT ALKERMES, INC. (US) 2022-06-30 WO disclosed
US-20220194958-A1 Substituted Macrocyclic Compounds and Related Methods of Treatment JPMORGAN CHASE BANK, N.A. AS ADMINISTRATIVE AGENT 2022-06-23 US disclosed
CN-112159421-A Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid 珠海奥博凯生物医药技术有限公司 2021-01-01 CN disclosed
CN-112159421-A Preparation method of 2-fluoro-4-methyl-3-pyridineboronic acid 珠海奥博凯生物医药技术有限公司 2021-01-01 CN disclosed
US-20200369672-A1 2,4,6,7-TETRAHYDRO-PYRAZOLO[4,3-D]PYRIMIDIN-5-ONE DERIVATIVES AND RELATED COMPOUNDS AS C5A RECEPTOR MODULATORS FOR TREATING VASCULITIS AND INFLAMMATORY DISEASES IDORSIA PHARMACEUTICALS LTD. (CH) 2020-11-26 US disclosed
WO-2019059161-A1 PYRIDONE COMPOUND AND AGRICULTURAL AND HORTICULTURAL GERMICIDE HAVING SAME AS ACTIVE INGREDIENT 三井化学アグロ株式会社 2019-03-28 WO disclosed
US-20160068525-A1 Fused Heterocyclic Compounds as Selective BMP Inhibitors VANDERBILT UNIVERSITY (US) 2016-03-10 US disclosed